Dive Brief:
- Olympus said Tuesday it has agreed to buy Israel-based BioProtect for $270 million to expand its product portfolio in oncology and urology.
- BioProtect makes a balloon spacer system that separates the prostate from other structures during cancer radiation treatment.
- The transaction is expected to increase patient access to BioProtect’s technology through Olympus’ global reach and relationships with healthcare providers.
Dive Insight:
BioProtect’s implant is designed to provide consistent spacing between the prostate and other critical structures, protecting healthy tissue during prostate cancer radiation. After treatment, the implant naturally degrades.
The balloon spacer was introduced commercially in 2023 and has been used in more than 11,000 procedures worldwide, helping to preserve gastrointestinal, urinary and sexual function for patients, Olympus said.
Tokyo-based Olympus said the acquisition will help it grow its portfolio in adjacent therapeutic areas related to endoscopy, including the gastrointestinal and urological fields.
BioProtect generated about $14.5 million in revenue in 2025 and employs 130 people. The acquisition is expected to be completed by the end of the second quarter.
In late 2025, Olympus announced a reorganization of its global endoscopy business that included the elimination of about 2,000 jobs.
